RNA can be designed to silence, express and edit specific genes, providing a flexible and powerful approach to treating diseases. COVID-19 mRNA vaccines, while an extraordinary accomplishment, have revealed that rapid development and scale-up, as well as access to innovative technologies, are needed to keep up with emerging variants and to usher in a new wave of genomic medicines to address other areas of unmet medical need. In this presentation, Dr. Lloyd Jeffs, Senior Director, Pharmaceutical Development shares insights into the technologies accelerating the development of RNA-lipid nanoparticle-based medicines from discovery to commercialization.